Sunflower Pharmaceutical: On March 9th, net short selling of 1,100 shares, with a total net sell-off of 17,500 shares over the past 3 days.

NightAirdropper · 2026-03-10T18:22:26+00:00

On March 9th, Cuihua Pharmaceutical bought in 2.8415 million yuan through margin financing, with a net purchase of 790,100 yuan. The margin financing balance was 125 million yuan. In terms of securities lending, there was a net sale of 1,100 shares, with a securities lending balance of 178,200 shares. The total margin financing and securities lending balance increased to 127 million yuan.

NightAirdropper

2026-03-10 18:22:26

Abstract generation in progress

Securities Star News: On March 9th, Huaihua Pharmaceutical (002737) had a margin buy-in of 2.8415 million yuan, a margin repayment of 2.0514 million yuan, with a net margin purchase of 790,100 yuan. The margin balance was 125 million yuan.

In terms of securities lending, on that day, 2,000 shares were sold short, 900 shares were repaid, resulting in a net short sale of 1,100 shares. The short interest was 178,200 shares. Over the past three trading days, there has been a continuous net short sale totaling 17,500 shares. In the past 20 trading days, 11 days showed net short sales.

The total margin and securities lending balance was 127 million yuan, up 0.64% from yesterday.

Quick Facts

Margin Trading and Securities Lending: Currently, individual investors participating in margin trading mainly need to meet two conditions: 1. Engage in securities trading for at least 6 months; 2. Account assets meet an average of 500,000 yuan over the previous 20 trading days. Margin trading targets: The Shanghai Stock Exchange will expand the number of main board stocks from the current 800 to 1,000, and the Shenzhen Stock Exchange will increase the number of stocks outside the registration system from 800 to 1,200.

The above content is compiled by Securities Star based on publicly available information, generated by AI algorithm (Net Xin Suan Bei 310104345710301240019), and does not constitute investment advice.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.